Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders

Current Treatment Options in Neurology

Volumn 12, Issue 6, 2010, Pages 529-538

  Wink, Logan K ^a   Erickson, Craig A ^a   McDougle, Christopher J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARIPIPRAZOLE; ATOMOXETINE; CITALOPRAM; CYCLOSERINE; ETHIONAMIDE; FLUOXETINE; GUANFACINE; ISONIAZID; MEMANTINE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OXYTOCIN; PIMOZIDE; PLACEBO; PSYCHOSTIMULANT AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE;

ADD ON THERAPY; AGITATION; AKATHISIA; ALZHEIMER DISEASE; ANOREXIA; ANTISOCIAL BEHAVIOR; ANXIETY DISORDER; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; BEHAVIOR THERAPY; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD PSYCHIATRY; CLINICAL TRIAL; COMMUNICATION DISORDER; COMPULSION; CONCENTRATION LOSS; CONSTIPATION; COPING BEHAVIOR; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSLIPIDEMIA; EARLY DIAGNOSIS; ENERGY METABOLISM; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART RATE; HUMAN; HYPERACTIVITY; HYPERGLYCEMIA; HYPERSALIVATION; HYPERTENSION; HYPOTENSION; IMPULSIVENESS; INCREASED APPETITE; INFANTILE AUTISM; INSOMNIA; INTELLECTUAL IMPAIRMENT; IRRITABILITY; MANIA; METABOLIC DISORDER; METABOLIC PARAMETERS; MOTOR DYSFUNCTION; NAUSEA; ONSET AGE; OUTCOME ASSESSMENT; PERSONALITY DISORDER; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; RASH; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SEIZURE; SEIZURE THRESHOLD; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOCIAL ADAPTATION; SOCIOPATHY; SOMNOLENCE; STEREOTYPY; SUICIDAL IDEATION; SYNCOPE; TARDIVE DYSKINESIA; TREMOR; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 77958504751     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-010-0091-8     Document Type: Review

References (26)

1. L Kanner 1943 Autistic disturbances of affective contact J Nerv Child 2 217 250
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4th. Washington DC: American Psychiatric Press; 1994.
3. P Howlin I Magiati T Charman 2009 Systematic review of early intensive behavioral interventions for children with autism Am J Intellect Dev Disabil 114 1 23 41 19143460
4. Research Units on Pediatric Psychopharmacology Autism Network 2005 Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity Arch Gen Psychiatry 62 11 1266 1274 10.1001/archpsyc.62.11.1266 (Pubitemid 41586926)
5. L Scahill MG Aman CJ McDougle, et al. 2006 A prospective open trial of guanfacine in children with pervasive developmental disorders J Child Adolesc Psychopharmacol 16 5 589 598 10.1089/cap.2006.16.589 17069547 (Pubitemid 44737213)
6. BL Handen R Sahl AY Hardan 2008 Guanfacine in children with autism and/or intellectual disabilities J Dev Behav Pediatr 29 4 303 308 10.1097/DBP. 0b013e3181739b9d 18552703
7. Physicians Desk Reference online. Available at http://www.pdr.net/home/ pdrHome.aspx. Accessed May 2010.
8. LE Arnold MG Aman AM Cook, et al. 2006 Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial J Am Acad Child Adolesc Psychiatry 45 10 1196 1205 10.1097/01.chi.0000231976.28719.2a 17003665 (Pubitemid 44465640)
9. DJ Posey RE Wiegand J Wilkerson, et al. 2006 Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders J Child Adolesc Psychopharmacol 16 5 599 610 10.1089/cap.2006.16.599 17069548 (Pubitemid 44739916)
10. Stahl SM: Essential Pharmacology The Prescriber's Guide. Revised and Updated Edition. New York: Cambridge University Press; 2006.
11. CJ McDougle ST Naylor DJ Cohen, et al. 1996 A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder Arch Gen Psychiatry 53 11 1001 1008 1:CAS:528:DyaK28XntFWnsrg%3D 8911223
12. E Hollander A Phillips W Chaplin, et al. 2005 A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism Neuropsychopharmacology 30 3 582 589 1:CAS:528: DC%2BD2MXhtlOrt74%3D 10.1038/sj.npp.1300627 15602505 (Pubitemid 40271160)
13. Autism Speaks Announces Results Reported for the Study of Fluoxetine in Autism (SOFIA), First Industry-Sponsored Trial for the Autism Clinical Trials Network (ACTN) 2009. New York, NY: Autism Speaks; February 18, 2009. Available at http://www.autismspeaks.org/press/as-announces-sofia-results.php. Accessed May 2010.
14. BH King E Hollander L Sikich, et al. 2009 Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism Arch Gen Psychiatry 66 6 583 590 1:CAS:528:DC%2BD1MXnvVOkt7k%3D 10.1001/archgenpsychiatry.2009.30 19487623 This National Institutes of Health-sponsored randomized controlled trial demonstrated lack of efficacy of citalopram in treating repetitive behaviors in children with autism and other PDDs
15. Research Units on Pediatric Psychopharmacology Autism Network 2002 Risperidone in children with autism and serious behavioral problems N Engl J Med 347 5 314 321 10.1056/NEJMoa013171 (Pubitemid 34815353)
16. RN Marcus R Owen L Kamen, et al. 2009 A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder J Am Acad Child Adolesc Psychiatry 48 11 1110 1119 10.1097/CHI.0b013e3181b76658 19797985 This study contributed to the FDA approval of aripiprazole for treatment of irritability in children and adolescents with autism
17. R Owen L Sikich RN Marcus, et al. 2009 Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder Pediatrics 124 6 1533 1540 10.1542/peds.2008-3782 19948625 This study contributed to the FDA approval of aripiprazole for treatment of irritability in children and adolescents with autism
18. Research Units on Pediatric Psychopharmacology Autism Network 2005 Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months Am J Psychiatry 162 7 1361 1369 10.1176/appi.ajp.162.7.1361 (Pubitemid 40905588)
19. K Komossa C Rummel-Kluge F Schmid, et al. 2009 Aripiprazole versus other atypical antipsychotics for schizophrenia Cochrane Database Syst Rev 4 CD006569 19821375
20. DJ Posey DL Kem NB Swiezy, et al. 2004 A pilot study of D-cycloserine in subjects with autistic disorder Am J Psychiatry 161 11 2115 2117 10.1176/appi.ajp.161.11.2115 15514414 (Pubitemid 39441414)
21. Posey DJ, Stigler KA, Erickson CA, et al.: A double-blind placebo-controlled study of D-cycloserine in children with autistic disorder [abstract P3.53:83]. Presented at the 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry Scientific Proceedings, Chicago, IL; October 29-November 1, 2008.
22. CA Erickson DJ Posey KA Stigler, et al. 2007 A retrospective study of memantine in children and adolescents with pervasive developmental disorders Psychopharmacology (Berl) 191 1 141 147 1:CAS:528:DC%2BD2sXhvVeis7Y%3D 10.1007/s00213-006-0518-9 (Pubitemid 46294942)
23. MG Chez Q Burton T Dowling, et al. 2007 Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability J Child Neurol 22 5 574 579 10.1177/0883073807302611 17690064 (Pubitemid 46951501)
24. K Macdonald TM Macdonald 2010 The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans Harv Rev Psychiatry 18 1 1 21 10.3109/10673220903523615 20047458
25. E Hollander J Bartz W Chaplin, et al. 2007 Oxytocin increases retention of social cognition in autism Biol Psychiatry 61 4 498 503 1:CAS:528: DC%2BD2sXhtlWjurk%3D 10.1016/j.biopsych.2006.05.030 16904652 (Pubitemid 46185336)
26. E Andari JR Duhamel T Zalla, et al. 2010 Promoting social behavior with oxytocin in high-functioning autism spectrum disorders Proc Natl Acad Sci USA 107 9 4389 4394 1:CAS:528:DC%2BC3cXjtlCitr4%3D 10.1073/pnas.0910249107 20160081